Glaukos vs NovoCure
GKOS and NVCR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GKOS and NVCR compare
Glaukos is the larger company, worth 9.2 times as much as NovoCure ($14.0B against $1.5B).
Glaukos grew revenue faster over the last twelve months (41.5% versus 12.9% for NovoCure).
NovoCure keeps more of each dollar of sales as profit, with a net margin of −16.8% compared with −30.7% at Glaukos.
NovoCure scores higher on the StockData Score (8 against 7 for Glaukos), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GKOS | NVCR |
|---|---|---|
| Size and price | ||
| Market cap | $14.0B | $1.5B |
| Share price | $237.60 | $13.15 |
| Change, 1 year | 208% | −2.4% |
| Change, 5 years | 317% | −87.6% |
| Beta (5Y) | 1.06 | 1.58 |
| Employees | 1,094 | 1,605 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 | 3 |
| Performance score | 2 (better) | 1 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 22.9× | 2.1× (better) |
| P/B | 20.5× | 4.4× (better) |
| FCF yield | −0.09% (better) | −1.6% |
| Fair value | $70.14 | $16.42 |
| Margin of safety | −239% | 19.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 41.5% (better) | 12.9% |
| Revenue growth, 5Y average | 17.7% (better) | 5.8% |
| Profitability | ||
| Gross margin | 60.7% | 77.0% (better) |
| Operating margin | −31.6% | −17.2% (better) |
| Net margin | −30.7% | −16.8% (better) |
| FCF margin | −2.0% (better) | −3.4% |
| Return on equity | −26.0% (better) | −35.2% |
| Return on invested capital | −24.9% (better) | −70.8% |
| Financial health | ||
| Debt / equity | – | 0.07 |
| Interest coverage | −39.4× | – |
| Current ratio | 5.04 (better) | 2.49 |
| Altman Z-score | 34.36 (better) | 0.54 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.24% |
| Shareholder yield | 0.00% (better) | −0.24% |
| Ownership | ||
| Held by institutions | 103% | 88.9% |
| Held by insiders | 5.3% | 3.0% |
| Insider net buying, 12 months | −$69.1M | −$3.3M (better) |
| Short interest, % of float | 6.9% | 9.9% |
Go deeper
- GKOS stock overview
- GKOS income statement
- GKOS valuation and score
- NVCR stock overview
- NVCR income statement
- NVCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.